profile.pharmafile.com
Subscribe to our Publications
http://profile.pharmafile.com/Subscribe.php
Subscribe to our Publications. Please note that selection is subject to the publication's Terms of Control. If you have any problems with this form please contact subscriptions@pharmafile.com. Please note that this is a paper subscription, if you qualify to receive our publication we will require your full mailing address. Congo, The Democratic Republic Of. TURKS and CAICOS ISLANDS. Turks and Caicos Islands. Virgin Islands, British. Virgin Islands, U.S.
pharmafile.com
Pharmafile - Sales and Marketing | Pharmafile
http://www.pharmafile.com/news/sales-and-marketing
Pharmafile - Sales and Marketing. Pfizer nabs EU approval for Xalkori for certain lung cancers. Xalkori (crizotinib) has been approved to treat patients with ROS1-positive advanced non-small cell lung cancer. The September issue of Pharmafocus is now live! Check out the latest news in the industry, plus special features on Brexit, cloud computing and trial transparency. FDA approves Novartis Enbrel biosimilar. This is the first biosimilar for the inflammatory disease drug to be approved in the US. Servic...
pharmafile.com
News | Pharmafile
http://www.pharmafile.com/news
Pfizer nabs EU approval for Xalkori for certain lung cancers. Xalkori (crizotinib) has been approved to treat patients with ROS1-positive advanced non-small cell lung cancer. The September issue of Pharmafocus is now live! Check out the latest news in the industry, plus special features on Brexit, cloud computing and trial transparency. AstraZeneca to pay 5.52 million to settle bribery probe. FDA approves Novartis Enbrel biosimilar. The power of PrEP. Valeant appoints new executive VP of finance and CFO.
pharmafile.com
Pharmafile - Business Services | Pharmafile
http://www.pharmafile.com/news/business-services
Pharmafile - Business Services. The September issue of Pharmafocus is now live! Check out the latest news in the industry, plus special features on Brexit, cloud computing and trial transparency. Chinese investors plan $1 billion US biotech site. Greenland Holdings, Ping An Trust, Agile Group and Poly Sino Capital joins forces to deliver a new San Fancisco-based R&D site. Pfizer’s Xalkori price drop secures NICE recommendation. Lung cancer drug receives thumbs up despite earlier rejection. PCI Pharma Ser...
pharmafile.com
Company Services | Pharmafile
http://www.pharmafile.com/compare-services
Enter a search term:. Category (Select a category to expand. Analytical and Laboratory Services. Media Buying and Planning. Conferencing, Events and Incentives. Naming and Verbal Identity. Naming and verbal identity. European Health Care and Trade Press. UK Healthcare and Trade Press. US Healthcare and Trade Press. Market and Product Development. Issues and Crisis Management. Travel and logistics management. Dedicated and syndicated sales teams. Pharmacy sales and educational programmes. Formulation (Ref...
pharmafile.com
Pharmafile - Medical Communications | Pharmafile
http://www.pharmafile.com/news/medical-communications
Pharmafile - Medical Communications. The September issue of Pharmafocus is now live! Check out the latest news in the industry, plus special features on Brexit, cloud computing and trial transparency. Top ten stories in the pharmaceutical industry this week. Check out the ten most popular articles on pharmafile.com this week. EMA accepts regulatory submission for proposed Herceptin biosimilar. Denali Therapeutics secures another $130 million for neurodegenerative disease research. The power of PrEP.
pharmafile.com
News | Pharmafile
http://www.pharmafile.com/news-listing
Pfizer nabs EU approval for Xalkori for certain lung cancers. Xalkori (crizotinib) has been approved to treat patients with ROS1-positive advanced non-small cell lung cancer. Recipharm establishes long term supply agreement with Tillotts Pharma AG. The September issue of Pharmafocus is now live! Check out the latest news in the industry, plus special features on Brexit, cloud computing and trial transparency. AstraZeneca to pay 5.52 million to settle bribery probe. FDA approves Novartis Enbrel biosimilar.
pharmafile.com
Pharmafile - UK | Pharmafile
http://www.pharmafile.com/news/uk
Parliamentary committee says CDF must make better use of taxpayer money. Scutiny of Government funded scheme continues as PAC says Cancer Drugs Fund reforms have to deliver better value in form of improved patient. Investigation questions Xarelto trial data accuracy. BMJ feature says device used in pivotal ROCKET-AF trial may give unreliable results but investigators say possible malfunctions would not have. Emerging markets top global R&D spending league. London launches new cancer drug development hub.
pharmafile.com
Pharmafile - Manufacturing and Production | Pharmafile
http://www.pharmafile.com/news/manufacturing-and-production
Pharmafile - Manufacturing and Production. The September issue of Pharmafocus is now live! Check out the latest news in the industry, plus special features on Brexit, cloud computing and trial transparency. Teva to lay off 236 in Pomona, New York. All employees are to be laid off in the run-up to the facility’s closure in February. Heart disease drug development is falling. The number of treatments for cardiovascular diseases in development has decreased since 1990, while cancer treatments are on the rise.
pharmafile.com
Home | Pharmafile
http://www.pharmafile.com/home
The September issue of Pharmafocus is now live! Check out the latest news in the industry, plus special features on Brexit, cloud computing and trial transparency. FDA approves Novartis Enbrel biosimilar. This is the first biosimilar for the inflammatory disease drug to be approved in the US. KaloBios cuts ties with former CEO Martin Shkreli, outlines ‘maniacal’ turnaround plan. Shkreli is no longer a stakeholder as he sells all of his remaining shares for $6 million. The power of PrEP.
SOCIAL ENGAGEMENT